Antineoplastic interferons are a type of
drug class that belong to the large family of cytokines and are
manufactured through the process of recombinant DNA technology.
Interferons are proteins produced by host cells infected with viruses,
bacteria, or tumor cells. They are best known as biologic antineoplastic
agents. Antineoplastic interferons enhance the immune system in many
ways. In recent years, the use of interferons in cancer chemotherapy has
grown. Antineoplastic interferons can be used therapeutically to treat
certain types of cancer such as chronic myelogenius leukemia.
Antineoplastic interferon drugs are also effective against viral
infections such as hepatitis B and C, human papillomavirus, etc. There
are mainly three types of antineoplastic interferons. Out of these, type
one interferons offer effective immunostimulator capacity and high
binding affinity to complex target proteins of the cell.
Based on type, the global antineoplastic
interferon drugs market can be segmented into alpha interferon, beta
interferon, and gamma interferon. The alpha interferon segment is likely
to expand at a significant pace during the forecast period, because
alpha interferons are monomeric i.e. they contain one chain and two
different receptor chains that help to bind different portion of
proteins. This is very effective in binding complex molecules of
pathogens. This feature makes alpha interferons effective in drug
development. In terms of disease condition, the global antineoplastic
interferon market can be categorized into angioblastoma, chronic
myelogenius leukemia, renal cell carcinoma, hepatitis B, hepatitis C,
and others. The hepatitis C segment is likely to expand at a prominent
pace during the forecast period, as the prevalence of hepatitis C is
increasing across the globe and antineoplastic interferon drugs are very
effective to treat it.
Increase in prevalence of infectious
viral diseases and cancer is a major factor fueling the global
antineoplastic interferon drugs market. Moreover, increase in research
and development activities to develop recombinant drugs is projected to
drive the global antineoplastic interferon drugs market during the
forecast period. However, certain side effects related to interferon
drug scuh as diarrhea, flatulence, abdominal pain, injection site
reaction, etc. are likely to hamper the market in the next few years.
In terms of region, the global
antineoplastic interferon drugs market can be segmented into North
America, Europe, Asia Pacific, Latin America, and Middle East &
Africa. North America dominates the global market. The region is
projected to account for a significant share of the global market during
the forecast period, due to rise in the prevalence of infectious
diseases, presence of highly developed health care system, and high
level of research and development activities to develop recombinant
drugs. Rise in geriatric population that is more prone to various
disease is one of the main factors likely to drive the market in Europe.
In Asia Pacific, the increasing prevalence of infectious diseases and
robust health care infrastructure are likely to fuel the market during
the forecast period. Rise in prevalence of diseases such as cancer and
viral infectious disease such as HCV, hepatitis C, etc. in Africa is
likely to augment the antineoplastic interferon drugs market in Middle
East & Africa during the forecast period.
Key players operating in the global
antineoplastic interferon drugs market are Merck & Co., Inc.
Novartis AG, Bayer AG, Biogen, and F. Hoffmann-La Roche Ltd. among
others.
No comments:
Post a Comment